{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:46:16Z","timestamp":1770511576982,"version":"3.49.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Heart J"],"DOI":"10.1093\/eurheartj\/ehw480","type":"journal-article","created":{"date-parts":[[2016,10,4]],"date-time":"2016-10-04T11:05:50Z","timestamp":1475579150000},"page":"ehw480","source":"Crossref","is-referenced-by-count":47,"title":["European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk"],"prefix":"10.1093","author":[{"given":"Ulf","family":"Landmesser","sequence":"first","affiliation":[]},{"given":"M.","family":"John Chapman","sequence":"additional","affiliation":[]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[]},{"given":"Baris","family":"Gencer","sequence":"additional","affiliation":[]},{"given":"Stephan","family":"Gielen","sequence":"additional","affiliation":[]},{"given":"G. Kees","family":"Hovingh","sequence":"additional","affiliation":[]},{"given":"Thomas F.","family":"L\u00fcscher","sequence":"additional","affiliation":[]},{"given":"David","family":"Sinning","sequence":"additional","affiliation":[]},{"given":"Lale","family":"Tokg\u00f6zo\u011flu","sequence":"additional","affiliation":[]},{"given":"Olov","family":"Wiklund","sequence":"additional","affiliation":[]},{"given":"Jose Luis","family":"Zamorano","sequence":"additional","affiliation":[]},{"given":"Fausto J.","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[]},{"name":"on behalf of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","sequence":"additional","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2016,10,27]]},"reference":[{"key":"2016102719433847000_ehw480v1.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi733"},{"key":"2016102719433847000_ehw480v1.2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-015-0772-9"},{"key":"2016102719433847000_ehw480v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.01.036"},{"key":"2016102719433847000_ehw480v1.4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw106"},{"key":"2016102719433847000_ehw480v1.5","doi-asserted-by":"crossref","unstructured":"Catapano AL Graham I De Backer G Wiklund O Chapman MJ Drexel H Hoes AW Jennings CS Landmesser U Pedersen TR Reiner \u017d Riccardi G Taskinen MR Tokgozoglu L Verschuren WM Vlachopoulos C Wood DA Zamorano JL ESC\/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2016; pii: ehw272. [Epub ahead of print].","DOI":"10.5603\/KP.2016.0157"},{"key":"2016102719433847000_ehw480v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.04.809"},{"key":"2016102719433847000_ehw480v1.7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw015"},{"key":"2016102719433847000_ehw480v1.8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw046"},{"key":"2016102719433847000_ehw480v1.9","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: a key modulator of cardiovascular health","volume":"14","author":"Seidah","year":"2014","journal-title":"Circ Res"},{"key":"2016102719433847000_ehw480v1.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054013"},{"key":"2016102719433847000_ehw480v1.11","doi-asserted-by":"publisher","DOI":"10.1038\/ng1161"},{"key":"2016102719433847000_ehw480v1.12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv563"},{"key":"2016102719433847000_ehw480v1.13","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2957"},{"key":"2016102719433847000_ehw480v1.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501031"},{"key":"2016102719433847000_ehw480v1.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500858"},{"key":"2016102719433847000_ehw480v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.07.028"},{"key":"2016102719433847000_ehw480v1.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.11.015"},{"key":"2016102719433847000_ehw480v1.18","unstructured":"Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS). ClinicalTrials.gov Identifier: NCT02207634. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02207634 (28 September 2016)."},{"key":"2016102719433847000_ehw480v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"2016102719433847000_ehw480v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2014.12.049"},{"key":"2016102719433847000_ehw480v1.21","doi-asserted-by":"publisher","DOI":"10.1177\/1741826711400545"},{"key":"2016102719433847000_ehw480v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.01.018"},{"key":"2016102719433847000_ehw480v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)00003-6"},{"key":"2016102719433847000_ehw480v1.24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv320"},{"key":"2016102719433847000_ehw480v1.25","unstructured":"The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1). ClinicalTrials.gov Identifier: NCT01975376. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01975376 (28 September 2016)."},{"key":"2016102719433847000_ehw480v1.26","unstructured":"The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2). ClinicalTrials.gov Identifier: NCT01975389. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01975389 (28 September 2016)."},{"key":"2016102719433847000_ehw480v1.27","unstructured":"GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound (GLAGOV). ClinicalTrials.gov Identifier: NCT01813422. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01813422 (28 September 2016)."},{"key":"2016102719433847000_ehw480v1.28","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht015"},{"key":"2016102719433847000_ehw480v1.29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht273"},{"key":"2016102719433847000_ehw480v1.30","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu274"},{"key":"2016102719433847000_ehw480v1.31","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000297"},{"key":"2016102719433847000_ehw480v1.32","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw028"},{"key":"2016102719433847000_ehw480v1.33","doi-asserted-by":"publisher","DOI":"10.1038\/nature13917"},{"key":"2016102719433847000_ehw480v1.34","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv289"},{"key":"2016102719433847000_ehw480v1.35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a2423"},{"key":"2016102719433847000_ehw480v1.36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn422"},{"key":"2016102719433847000_ehw480v1.37","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001236"},{"key":"2016102719433847000_ehw480v1.38","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv602"},{"key":"2016102719433847000_ehw480v1.39","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv157"},{"key":"2016102719433847000_ehw480v1.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"2016102719433847000_ehw480v1.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2014.02.021"},{"key":"2016102719433847000_ehw480v1.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.01.008"},{"key":"2016102719433847000_ehw480v1.43","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv370"},{"key":"2016102719433847000_ehw480v1.44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61399-4"},{"key":"2016102719433847000_ehw480v1.45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61374-X"},{"key":"2016102719433847000_ehw480v1.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61965-6"},{"key":"2016102719433847000_ehw480v1.47","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv043"},{"key":"2016102719433847000_ehw480v1.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.09.039"},{"key":"2016102719433847000_ehw480v1.49","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.jacl.2014.03.002","article-title":"An assessment by the Statin Intolerance Panel: 2014 update","volume":"8(3 Suppl)","author":"Guyton","year":"2014","journal-title":"J Clin Lipidol"},{"key":"2016102719433847000_ehw480v1.50","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8(3 Suppl)","author":"Rosenson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"2016102719433847000_ehw480v1.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.08.006"},{"key":"2016102719433847000_ehw480v1.52","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.25790"},{"key":"2016102719433847000_ehw480v1.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.019"},{"key":"2016102719433847000_ehw480v1.54","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.3608"},{"key":"2016102719433847000_ehw480v1.55","unstructured":"National Institute for Health and Care Excellence. Hypercholesterolaemia (primary) and dyslipidaemia (mixed)\u2014alirocumab [ID779]. NICE in development [GID-TAG512]. https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-tag512 (28 September 2016)."},{"key":"2016102719433847000_ehw480v1.56","unstructured":"National Institute for Health and Care Excellence. Hypercholesterolaemia (primary), dyslipidaemia (mixed)\u2014evolocumab [ID765]. NICE technology appraisal guidance [TA394]. https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-tag498 (28 September 2016)."}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/38\/29\/2245\/19377893\/ehw480.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T07:05:52Z","timestamp":1568444752000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-lookup\/doi\/10.1093\/eurheartj\/ehw480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,27]]},"references-count":56,"alternative-id":["10.1093\/eurheartj\/ehw480"],"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehw480","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,27]]}}}